 OPKO Health Incs NASDAQ: OPK subsidiary EirGen Pharma has agreed to develop and commercialize Rayaldee to treat secondary hyperparathyroidism in patients with stage 34 chronic kidney disease with Nicoya Therapeutics in Greater China. Nicoya will make an upfront payment to OPKO of 5 million and an additional 5 million payment during the first 12 months of the agreement or upon Nicoya achieving a certain predetermined development milestone. 